UBS Group
AMLX icon

UBS Group’s Amylyx Pharmaceuticals AMLX Stock Holding History

UBS Group’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,900
Closed -$602K – 9421
2023
Q2 		$602K Hold
27,900
– – ﹤0.01% 4669
2023
Q1 		$819K Hold
27,900
– – ﹤0.01% 4279
2022
Q4 		$1.03M Buy
+27,900
New +$990K ﹤0.01% 4043

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.23B AUM 121.47% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

UBS Group's AMLX Position: Q3 2026 in Review

UBS Group reduced its Amylyx Pharmaceuticals (AMLX) stake by 57% in Q3 2026, selling an estimated $4.12M and leaving 116,270 shares worth $3.38M. The position accounts for ﹤0.01% of the portfolio, ranked #4502.

UBS Group first reported a position in AMLX in Q1 2022 and has held it in 19 quarters since. The position peaked at $19.1M in Q3 2025. 107 funds tracked by Wall St. Rank hold AMLX as of Q3 2026.

  • UBS Group held 116,270 shares of Amylyx Pharmaceuticals worth $3.38M as of Q3 2026.
  • UBS Group sold 155,611 Amylyx Pharmaceuticals shares in Q3 2026, an estimated $4.12M.
  • Amylyx Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #4502 holding.
  • UBS Group first reported a position in Amylyx Pharmaceuticals in Q1 2022 and has held it in 19 quarters since.
  • UBS Group's Amylyx Pharmaceuticals position peaked at $19.1M in Q3 2025.
  • 107 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.